Innovent to Present Clinical Data on Novel Molecules at WCLC and ESMO 2024

SAN FRANCISCO and SUZHOU, China, Aug. 28, 2024 -- Innovent Biologics, Inc. (HKEX: 01801), a prominent biopharmaceutical company specializing in developing, manufacturing, and commercializing high-quality medications for treating major diseases such as oncology, cardiovascular and metabolic disorders, autoimmune diseases, and ophthalmology, is set to present nearly 20 clinical data on its innovative oncology molecules at two prestigious conferences: the World Conference on Lung Cancer (WCLC) from September 7-10, 2024, in San Diego, U.S., and the European Society of Medical Oncology (ESMO) from September 13-17, 2024, in Barcelona, Spain.

Highlighting the presentations at these conferences will be oral sessions and multiple clinical results showcasing Innovent's novel oncology molecules. At WCLC, the company will present updated Phase 1 results for IBI363 (a first-in-class PD-1/IL-2 bispecific antibody) in non-small cell lung cancer (NSCLC) at doses up to 3 mg/kg. Additionally, updated Phase 1 results of IBI363 combined therapy in colorectal cancer will be revealed at ESMO. Furthermore, WCLC will feature an oral presentation on the updated pivotal Phase 2 results of Dupert® (fulzerasib, a KRAS G12C inhibitor) in NSCLC, along with Phase 1 results of IBI354 (a HER2 ADC) in HER2+ solid tumors at ESMO, and various clinical outcomes for TYVYT® (sintilimab injection).

Dr. Hui Zhou, Senior Vice President of Innovent, expressed excitement about presenting an extensive set of clinical data for their next-generation bispecific antibodies and ADC molecules. These presentations span across notable medical conferences in 2024, including ASCO, ESMO Plenary, ESMO GI in June, WCLC, and ESMO in September. Dr. Zhou highlighted the promising preliminary efficacy and safety signals of these innovative candidates, emphasizing their potential for further development and clinical value. Innovent, equipped with advanced technology platforms and a robust pipeline in "IO+ADC" areas, remains steadfast in its mission to enhance cancer treatment by providing doctors and patients with more innovative, effective, and safe therapeutic options.

Several abstracts will be presented at WCLC and ESMO:

WCLC Oral Sessions:
1. First-in-Class PD-1/IL-2 Bispecific Antibody IBI363 in Advanced NSCLC:
- Presenter: Jianya Zhou, The First Affiliated Hospital of Zhejiang University School of Medicine.
- Date: September 10, 2024, 13:37-13:42 PDT.

2. KRAS G12C Inhibitor IBI351 in Advanced NSCLC:
- Presenter: Qing Zhou, Guangdong People's Hospital.
- Date: September 9, 2024, 15:52-16:02 PDT.

3. Neoadjuvant Sintilimab plus Chemotherapy in EGFR-mutant NSCLC:
- Presenter: C. Zhang, Guangdong Lung Cancer Institute.
- Date: September 10, 2024, 15:48-15:53 PDT.

4. First-Line Treatment of Pulmonary Lymphoepithelioma-like Carcinoma:
- Presenter: C. Zhou, The First Affiliated Hospital of Medical University.
- Date: September 10, 2024, 13:32-13:37 PDT.

ESMO Oral Sessions:
1. IBI354 (anti-HER2 ADC) in Advanced Solid and Breast Cancer:
- Presenter: Christina Teng, Scientia Clinical Research, Australia.
- Date: September 15, 2024, 9:15-9:20 AM CEST.

2. IBI354 in Advanced Gynecological Cancers:
- Presenter: Jin Shu, Chongqing University Affiliated Cancer Hospital.
- Date: September 15, 2024, 15:45-15:50 CEST.

WCLC Posters:
1. Neoadjuvant Chemoimmunotherapy in Resectable NSCLC:
- Presenter: K. Ma, First Hospital of Jilin University.
- Date: September 7, 2024, 11:58-11:59 AM PDT.

2. Sintilimab Combined with Anlotinib in KRAS-Mutant NSCLC:
- Presenter: F. Wang, Peking University Shenzhen Hospital.
- Date: September 9, 2024, 18:30 PDT.

ESMO Posters:
1. PD-1/IL-2 Bispecific Antibody IBI363 + Bevacizumab in Advanced CRC:
- Presenter: Zhen Yu Lin, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

2. IBI354 in Advanced Gastrointestinal Cancers:
- Presenter: Jifang Gong, Peking University Cancer Hospital.

3. Hepatic Artery Infusion Chemotherapy Plus Sintilimab for Unresectable Hepatocellular Carcinoma:
- Presenter: Huikai Li, Tianjin Medical University Cancer Institute & Hospital.

4. Fruquintinib Combined with Sintilimab and Chemotherapy in Advanced NSCLC:
- Presenter: Pei Ma, Jiangsu Province Hospital.

Innovent Biologics continues its pioneering efforts to develop innovative treatments, aiming to bring new hope to patients worldwide through its dedicated research and development in the biopharmaceutical industry.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!